Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
p.DOM-WT1-126
- Development stage
- Unknown
- Lead developer
- University Hospital Southampton NHS Foundation Trust
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
p.DOM-WT1-126 is a DNA vaccine developed by the University Hospital Southampton NHS Foundation Trust for the treatment of chronic myeloid leukemia (CML) and acute myeloid leukemia (AML). It consists of a DNA plasmid encoding a specific epitope of the Wilms' tumor 1 (WT1) protein, a tumor-associated antigen that is highly expressed in various leukemias. The vaccine is designed to stimulate the patient's immune system, particularly cytotoxic T lymphocytes (CTLs), to recognize and destroy WT1-expressing malignant cells. In clinical trials, it is typically administered via intramuscular injection followed by electroporation to enhance DNA uptake and is often used in a dual-vaccine regimen alongside p.DOM-WT1-37.
- Other names
- p.DOM-WT1-126 DNA vaccine
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)
Beyond the preview
Go deeper on p.DOM-WT1-126.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on p.DOM-WT1-126.